ClinicalTrials.gg

Program

enfortumab vedotin

Also written as “Enfortumab Vedotin”, “Enfortumab vedotin” and “enfortumab vedotin (EV)”.

Its studies are mostly in Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Neoplasms · Triple Negative Breast Neoplasms · Non-Muscle Invasive Bladder Neoplasms, led by Astellas Pharma.

Furthest: phase 4, since Mar 3, 202513 company-led studies, 5 open or runningNext primary completion: Dec 31, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma135 open or runningphase 4since Mar 3, 2025Jul 29, 2011Dec 31, 2026phase 4 · NCT06862219

Also a collaborator on its studies: Pfizer, Merck and Gilead Sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2011First study: phase 1 study in NeoplasmsFirst studyNCT01409135 · 34 enrolled · United States, Canada
  2. Mar 18, 2014Phase 1 study in Metastatic Urothelial Cancer and Other Malignant Solid TumorsNCT02091999 · 213 enrolled · United States, Canada
  3. Mar 1, 2017Phase 1 study in Carcinoma, Transitional CellNCT03070990 · 19 enrolled · Japan
  4. Jul 13, 2017Phase 2 study in Carcinoma, Transitional CellNCT03219333 · 219 enrolled · United States, France, Germany and more
  5. Sep 18, 2017Phase 2 study in Carcinoma, Transitional CellNCT03288545 · 348 enrolled · United States, Canada, France and more
  6. Mar 16, 2018Phase 3 study in Ureteral NeoplasmsNCT03474107 · 608 enrolled · United States, Argentina, Australia and more
  7. Jan 6, 2020Phase 3 study in Urothelial CancerNCT04223856 · 886 enrolled · United States, Argentina, Australia and more
  8. Jan 9, 2020Phase 2 study in Triple Negative Breast NeoplasmsNCT04225117 · 329 enrolled · United States, Canada, Japan
  9. Aug 2, 2021Phase 2 study in Metastatic Urothelial CancerNCT04995419 · 40 enrolled · China
  10. Aug 16, 2021Phase 1 study in Urinary Bladder NeoplasmsNCT05014139 · 37 enrolled · United States, Canada, France and more
  11. Mar 3, 2025Phase 4 study in Carcinoma, Transitional CellNCT06862219 · 100 planned · India
  12. Mar 13, 2026Phase 2 study in Muscle-invasive Bladder CancerNCT07475806 · 240 planned · United States, Australia, Canada and more
  13. Apr 29, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07566156 · 390 planned · United States, Canada, South Korea and more

Ahead

  1. Dec 31, 2026Primary completion: phase 4 study in Carcinoma, Transitional CellNCT06862219
  2. Nov 30, 2027Primary completion: phase 2 study in Muscle-invasive Bladder CancerNCT07475806
  3. Mar 31, 2030Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT07566156

TargetBeta

NECTIN4 →read by rule
“An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and ”NCIt, by rule
“Nectin-4 binding agent”ChEMBL 37, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
notiretatug rezetecanJiangsu HengRui Medicinephase 314
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 313
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 36
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07566156Urinary Bladder Neoplasms · United States, Canada, South Korea and more3RecruitingMar 31, 2030390
NCT07475806Muscle-invasive Bladder Cancer · United States, Australia, Canada and more2RecruitingNov 30, 2027240
NCT06862219Carcinoma, Transitional Cell · India4RecruitingDec 31, 2026100
NCT05014139Urinary Bladder Neoplasms · United States, Canada, France and more1TerminatedSep 22, 202537
NCT04995419Metastatic Urothelial Cancer · China2CompletedMay 13, 202240
NCT04225117Triple Negative Breast Neoplasms · United States, Canada, Japan2Active, not recruitingFeb 25, 2025329
NCT04223856Urothelial Cancer · United States, Argentina, Australia and more3Active, not recruitingAug 8, 2023886
NCT03474107Ureteral Neoplasms · United States, Argentina, Australia and more3CompletedJul 15, 2020608
NCT03288545Carcinoma, Transitional Cell · United States, Canada, France and more2TerminatedFeb 20, 2026348
NCT03219333Carcinoma, Transitional Cell · United States, France, Germany and more2CompletedOct 27, 2020219
NCT03070990Carcinoma, Transitional Cell · Japan1CompletedFeb 25, 201919
NCT02091999Metastatic Urothelial Cancer and Other Malignant Solid Tumors · United States, Canada1CompletedDec 7, 2022213
NCT01409135Neoplasms · United States, Canada1CompletedApr 27, 201534

How it is read

Names in the registry

  • “Enfortumab Vedotin”, 7 entries
  • “Enfortumab vedotin”, 6 entries
  • “enfortumab vedotin”, 3 entries
  • “enfortumab vedotin (EV)”, 2 entries
  • “Enfortumab vedotin (EV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.